{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T12:30:44Z","timestamp":1787229044863,"version":"build-2736575974"},"reference-count":21,"publisher":"BMJ","issue":"9","funder":[{"name":"Beijing Marathon of Hope, Cancer Foundation of China","award":["NCC3954"],"award-info":[{"award-number":["NCC3954"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Clin Pathol"],"accepted":{"date-parts":[[2026,5,25]]},"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>\n                      While kinase-altered spindle cell tumours were classically recognised in paediatric superficial soft tissues, recent literature indicates an expanding clinicopathologic spectrum. This study investigates a cohort of\n                      <jats:italic>RAF\/BRAF<\/jats:italic>\n                      -altered mesenchymal tumours to further characterise their presentations in adults, deep-seated\/visceral locations, variable immunophenotypes and complex molecular evolution.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Eight molecularly confirmed\n                      <jats:italic>RAF\/BRAF<\/jats:italic>\n                      -altered mesenchymal tumours were retrospectively evaluated. Clinical characteristics, histomorphology, immunohistochemistry, targeted next-generation sequencing profiles and follow-up data were comprehensively analysed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The cohort comprised seven females and one male (median age, 34.5 years). Tumours arose in soft tissues (n=5, including the deep pelvis) and visceral organs (n=3; two breast, one lung). Histologically, the neoplasms exhibited a broad morphologic spectrum: three demonstrated low-grade spindle cell morphology, whereas five displayed high-grade pleomorphic or fibrosarcoma-like features, including one pelvic tumour mimicking myxoid leiomyosarcoma. Immunophenotypes diverged significantly with histologic grade: low-grade tumours retained CD34 and S100 coexpression, whereas high-grade lesions consistently lost both markers, with one case exhibiting focal Desmin positivity. Molecular profiling revealed ubiquitous mitogen-activated protein kinase pathway activation, identifying six kinase gene fusions (including novel\n                      <jats:italic>IQSEC1::RAF1<\/jats:italic>\n                      and\n                      <jats:italic>PLEKHH3::BRAF<\/jats:italic>\n                      variants) and two\n                      <jats:italic>BRAF<\/jats:italic>\n                      V600E mutations. High-grade tumours frequently harboured concurrent tumour suppressor gene alterations (eg,\n                      <jats:italic>TP53<\/jats:italic>\n                      ,\n                      <jats:italic>PTEN<\/jats:italic>\n                      ). Notably, one pelvic tumour exhibited a trunk\n                      <jats:italic>NTRK1<\/jats:italic>\n                      mutation alongside a subclonal\n                      <jats:italic>BRAF<\/jats:italic>\n                      V600E mutation. Notably, despite the alarming high-grade histomorphology in several cases, clinical behaviour remained relatively indolent, with no disease-related deaths to date.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      <jats:italic>RAF\/BRAF<\/jats:italic>\n                      -driven mesenchymal tumours possess a broader clinicopathologic spectrum than traditionally recognised, frequently affecting adults and deep\/visceral sites. Their inherently variable immunophenotypes and the presence of high-grade morphologic features do not strictly predict an aggressive clinical trajectory. Comprehensive molecular profiling is essential to refine diagnostic criteria, accurately identify these neoplasms, and elucidate the genomic events associated with tumour progression.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jcp-2026-210784","type":"journal-article","created":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T17:20:42Z","timestamp":1780507242000},"page":"620-628","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Mesenchymal neoplasms with RAF\/BRAF alterations: eight cases revealing novel fusions, V600E mutation and clonal evolution"],"prefix":"10.1136","volume":"79","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-6424-0664","authenticated-orcid":false,"given":"Xiaolong","family":"Feng","sequence":"first","affiliation":[{"name":"Department of Pathology, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianming","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Medical Pathology, Jiangxi Cancer Hospital, Nanchang, Nanchang, 330029, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiwei","family":"Hao","sequence":"additional","affiliation":[{"name":"Department of Pathology, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiacong","family":"Wei","sequence":"additional","affiliation":[{"name":"Department of Pathology, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqi","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Pathology, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaru","family":"Wen","sequence":"additional","affiliation":[{"name":"Department of Pathology, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Cao","sequence":"additional","affiliation":[{"name":"Department of Pathology, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulu","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Pathology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, 230036, China"},{"name":"Intelligent Pathology Institute, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, 230036, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihua","family":"Gong","sequence":"additional","affiliation":[{"name":"Department of Pathology, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,6,3]]},"reference":[{"key":"2026082005150917000_79.9.620.1","doi-asserted-by":"publisher","DOI":"10.1002\/gcc.22671"},{"key":"2026082005150917000_79.9.620.2","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/path.6260","article-title":"Comprehensive clinicopathological, molecular, and methylation analysis of mesenchymal tumors with NTRK and other kinase gene aberrations","volume":"263","author":"Klub\u00ed\u010dkov\u00e1","year":"2024","journal-title":"J Pathol"},{"key":"2026082005150917000_79.9.620.3","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000000938"},{"key":"2026082005150917000_79.9.620.4","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1111\/his.14082","article-title":"Recurrent RET gene fusions in paediatric spindle mesenchymal neoplasms","volume":"76","author":"Davis","year":"2020","journal-title":"Histopathology"},{"key":"2026082005150917000_79.9.620.5","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1038\/s41379-021-00806-w","article-title":"Novel BRAF gene fusions and activating point mutations in spindle cell sarcomas with histologic overlap with infantile fibrosarcoma","volume":"34","author":"Penning","year":"2021","journal-title":"Mod Pathol"},{"key":"2026082005150917000_79.9.620.6","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s00428-022-03368-7","article-title":"RNA-sequencing of myxoinflammatory fibroblastic sarcomas reveals a novel SND1::BRAF fusion and 3 different molecular aberrations with the potential to upregulate the TEAD1 gene including SEC23IP::VGLL3 and TEAD1::MRTFB gene fusions","volume":"481","author":"Klub\u00ed\u010dkov\u00e1","year":"2022","journal-title":"Virchows Arch"},{"key":"2026082005150917000_79.9.620.7","doi-asserted-by":"crossref","unstructured":"Michal M , Ud Din N , Svajdler M , et al . Tfg::Met-rearranged soft tissue tumor: A rare infantile neoplasm with a distinct low-grade triphasic morphology. 2023;62. doi:10.1002\/gcc.23111","DOI":"10.1002\/gcc.23111"},{"key":"2026082005150917000_79.9.620.8","doi-asserted-by":"crossref","unstructured":"Offer K , McGuire MT , Song K , et al . Activity of Type II RAF Inhibitor Tovorafenib in a Pediatric Patient With a Recurrent Spindle Cell Sarcoma Harboring a Novel SNX8-BRAF Gene Fusion. JCO Precis Oncol 2023;7. doi:10.1200\/PO.23.00065","DOI":"10.1200\/PO.23.00065"},{"key":"2026082005150917000_79.9.620.9","doi-asserted-by":"crossref","unstructured":"Zhao M , Song J , Yin X , et al . ALK-rearranged mesenchymal neoplasms: a clinicopathological and molecular study of eight additional cases of an emerging group of tyrosine kinase fusion mesenchymal tumours. J Clin Pathol 2024. doi:10.1136\/jcp-2024-209521. [Epub ahead of print: 4 Jun 2024].","DOI":"10.1136\/jcp-2024-209521"},{"key":"2026082005150917000_79.9.620.10","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1369046","article-title":"Case report: Primary sarcoma of the mandible with a novel SLMAP-BRAF fusion","volume":"14","author":"Zhou","year":"2024","journal-title":"Front Oncol"},{"key":"2026082005150917000_79.9.620.11","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1111\/his.15445","article-title":"RAF1-rearranged spindle cell neoplasm: a clinicopathological and molecular genetic study of six cases with review of the literature","volume":"87","author":"Zhu","year":"2025","journal-title":"Histopathology"},{"key":"2026082005150917000_79.9.620.12","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25042366","article-title":"NTRK Therapy among Different Types of Cancers, Review and Future Perspectives","volume":"25","author":"Theik","year":"2024","journal-title":"Int J Mol Sci"},{"key":"2026082005150917000_79.9.620.13","doi-asserted-by":"crossref","first-page":"321","DOI":"10.2217\/pme-2022-0070","article-title":"Cost-effectiveness of alternative NTRK testing strategies in cancer patients followed by histology-independent therapy with entrectinib: an analysis of three European countries","volume":"20","author":"Vellekoop","year":"2023","journal-title":"Per Med"},{"key":"2026082005150917000_79.9.620.14","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.jval.2022.08.006","article-title":"Cost-Effectiveness Analysis of Treating Patients With NTRK-Positive Cancer With the Histology-Independent Therapy Entrectinib","volume":"26","author":"Huygens","year":"2023","journal-title":"Value Health"},{"key":"2026082005150917000_79.9.620.15","doi-asserted-by":"crossref","DOI":"10.1002\/gcc.23205","article-title":"Kinase fusion positive intra-osseous spindle cell tumors: A series of eight cases with review of the literature","volume":"63","author":"Suurmeijer","year":"2024","journal-title":"Genes Chromosomes Cancer"},{"key":"2026082005150917000_79.9.620.16","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1002\/gcc.22846","article-title":"Emerging soft tissue tumors with kinase fusions: An overview of the recent literature with an emphasis on diagnostic criteria","volume":"59","author":"Antonescu","year":"2020","journal-title":"Genes Chromosomes Cancer"},{"key":"2026082005150917000_79.9.620.17","doi-asserted-by":"crossref","first-page":"51","DOI":"10.4048\/jbc.2024.0284","article-title":"Recent Advances in Malignant Phyllodes Tumors of the Breast","volume":"28","author":"Lee","year":"2025","journal-title":"J Breast Cancer"},{"key":"2026082005150917000_79.9.620.18","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2025.1418537","article-title":"MAPK-targeted therapies in non-gastrointestinal stromal tumor soft tissue sarcomas: current landscape and future directions","volume":"15","author":"Al Jarroudi","year":"2025","journal-title":"Front Oncol"},{"key":"2026082005150917000_79.9.620.19","doi-asserted-by":"crossref","DOI":"10.1038\/s41392-023-01705-z","article-title":"Targeting the RAS\/RAF\/MAPK pathway for cancer therapy: from mechanism to clinical studies","volume":"8","author":"Bahar","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"2026082005150917000_79.9.620.20","doi-asserted-by":"crossref","DOI":"10.3390\/ijms27010214","article-title":"Targeting the MAPK Pathway in Cancer","volume":"27","author":"Kadasah","year":"2025","journal-title":"Int J Mol Sci"},{"key":"2026082005150917000_79.9.620.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2013.02.035"}],"container-title":["Journal of Clinical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jcp-2026-210784","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T12:15:47Z","timestamp":1787228147000},"score":1,"resource":{"primary":{"URL":"https:\/\/jcp.bmj.com\/lookup\/doi\/10.1136\/jcp-2026-210784"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,3]]},"references-count":21,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,8,20]]},"published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.1136\/jcp-2026-210784"],"URL":"https:\/\/doi.org\/10.1136\/jcp-2026-210784","relation":{},"ISSN":["0021-9746","1472-4146"],"issn-type":[{"value":"0021-9746","type":"print"},{"value":"1472-4146","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,3]]}}}